CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for FutureChem Co Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

FutureChem Co Ltd
2F, 21, Yeonmujang 3-gil, Seongdong-gu
Phone: +82 24973114p:+82 24973114 SEOUL, 04794  South Korea Ticker: 220100220100
Business Summary
FutureChem Co Ltd is a Korea-based company principally engaged in the development, manufacture and distribution of radiopharmaceuticals. The Company develops and manufactures radiopharmaceuticals including radiopharmaceuticals for diagnosis of various cancers such as lung cancer and prostate cancer, and for the early diagnosis of Parkinson's disease and Alzheimer's disease. The Company also develops and manufactures automatic synthesis modules such as disposable cassettes and reagent kits, produce of photon emission tomography (PET) and single photon emission computed tomography (SPECT) precursors for radiopharmaceuticals and produce other chemical products.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202412/31/2024Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
2836 Biological products, except diagnostic substances
3841 Surgical and medical instruments and apparatus

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
President, Chief Executive Officer, Director Dae YunJi 61
Chief Financial Officer, Assistant Managing Director Yeong YilYoo 50
Chief Technology Officer, Assistant Managing Director Hui SeopGil 52
7 additional Officers and Directors records available in full report.

General Information
Number of Employees: 47 (As of 6/30/2017)
Outstanding Shares: 22,096,928 (As of 12/31/2024)
Shareholders: 12,404
Stock Exchange: KDQ
Fax Number: +82 230108516


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, April 19, 2025